1. Introduction {#sec1-ijerph-17-00310}
===============

As the prevalence of type 2 diabetes mellitus (T2DM) increases, the magnitude of disability secondary to diabetic eye disease-related complications likewise will increase \[[@B1-ijerph-17-00310]\]. Worldwide, the estimated overall prevalence of diabetic retinopathy (DR) is 34.6%, while that of vision-threatening diabetic retinopathy is 10.2% \[[@B2-ijerph-17-00310]\]. In Kelantan, a state in Malaysia which has one of the highest rates of undiagnosed diabetes, the prevalence of DR has been estimated to be 39.3% \[[@B3-ijerph-17-00310],[@B4-ijerph-17-00310]\]. In line with the higher prevalence of DR is in developing regions, diabetic patients in emerging nations are especially vulnerable to vision-related functional impairment, especially with more severe grades of retinopathy \[[@B5-ijerph-17-00310],[@B6-ijerph-17-00310]\]. Recognizing that DR is merely one biomarker of the underlying widespread systemic microvascular effects of abnormal glucose metabolism \[[@B7-ijerph-17-00310]\], it is not surprising that patients with DR represent a major public health concern. The health-care costs of patients with DR complications are almost double that of those without the complication, making the societal burden of retinopathy substantial \[[@B8-ijerph-17-00310]\].

In patients with proliferative diabetic retinopathy (PDR) complicated by persistent vitreous hemorrhage (VH) or tractional retinal detachment (TRD), pars plana vitrectomy is the only option which offers the potential for patients to regain some degree of their visual function. Unfortunately, although the anatomical results are often excellent, the functional outcome leaves much to be desired \[[@B9-ijerph-17-00310]\]. For those patients who do improve post vitrectomy, the gains may be short-lived, due to various causes including recurrent vitreous hemorrhage (VH), cataract, epiretinal membrane (ERM) formation, retinal detachment and neovascular glaucoma \[[@B10-ijerph-17-00310],[@B11-ijerph-17-00310],[@B12-ijerph-17-00310],[@B13-ijerph-17-00310],[@B14-ijerph-17-00310]\]. This study therefore aimed to estimate the survival time of visual gains and its associated prognostic factors in patients with visual improvement post vitrectomy for complications of PDR.

2. Materials and Methods {#sec2-ijerph-17-00310}
========================

2.1. Study Design and Population {#sec2dot1-ijerph-17-00310}
--------------------------------

This was a retrospective cohort study involving analysis of medical records of 134 patients who underwent vitrectomy surgery from 1 January 2012 to 31 December 2016 for complications of PDR at Hospital Raja Perempuan Zainab II Kelantan, Malaysia. The patients' medical records were reviewed until 31 December 2017.

The patients were followed up at the ophthalmology clinic of this hospital. All cases were 20 or 23-gauge primary virectomy with or without tamponade (silicone oil or perfluoropropane gas). Inclusion criteria for the study were: (1) Pseudophakic T2DM patients who underwent primary vitrectomy surgery from 2012 to 2016 for complications of PDR; (2) patients in the group above who experienced visual gains post-surgery (a post-operative gain of ≥0.3 log of minimum angle of resolution (logMAR), sustained on two subsequent visits, was considered evidence of visual improvement); (3) patients on follow up in the ophthalmology clinic after vitrectomy surgery. Exclusion criteria included: (1) Patients with pre-existing concomitant ocular disease e.g., ocular trauma, lens dislocation, macular hole, ERM; (2) incomplete data records for the main variables of interest (more than 30).

2.2. Measures {#sec2dot2-ijerph-17-00310}
-------------

*Outcomes*. The outcome for this study was time to vision loss after vitrectomy surgery and the event of interest was vision loss. The time to vision loss was recorded from day one post vitrectomy until the vision deteriorated during the follow up period. Evaluation of vision loss was conducted by checking the logMAR visual acuity in the patients' medical records. During the post-operative follow up period, the visual acuity of each patient was measured at day one, week one, week six, month three, month six, and thereafter six-monthly until the last date of follow up. Counting fingers, hand movements, perception of light and no light perception were assigned the values 1.85, 2.3, 2.6, and 2.9 respectively. Subjects were considered to have vision loss when their visual acuity dropped by ≥0.3 LogMar. Censored observations were patients whose visual acuity was maintained until the end of study and those who were lost to follow up. Time for the censored observations was recorded from day one post vitrectomy until the end of the study for patients who maintained their visual acuity, or until the last follow-up date for patients who dropped out from the study.

*Predictors*. Covariates of interest included: socio-demographic characteristics (age; gender; ethnicity; family history of DM); clinical characteristics (duration of DM; anti-diabetic medication); pre-operative features (VH; TRD involving the macula; combined TRD with rhegmatogenous retinal detachment (RRD); laterality; pre-operative iris neovascularization (NVI); pre-operative visual acuity); premorbid conditions (hypertension; ischemic heart disease (IHD); chronic kidney disease; cerebrovascular event); and post-operative complications (post-op VH; post-op TRD; post-op RRD; post-op NVI; post-op ERM).

2.3. Data Analysis {#sec2dot3-ijerph-17-00310}
------------------

The statistical analysis used in this study was survival analysis. In survival analysis, interest centers on a group of individuals for each of whom there is defined point event, often called failure, occurring after a length of time, called failure time, or survival time. A descriptive analysis of socio-demographic, clinical characteristics, premorbid conditions, and post-operative complications was performed using frequency and percentage for categorical variables; while means and standard deviations were used for numerical variables.

Kaplan--Meier analysis was used to determine the survival time of visual acuity among patients with visual improvement post vitrectomy for complications of PDR. The survival time was calculated as the median time taken for survivors (in this case, patients with improved vision) to be equal or less than 50% of the total; i.e., the timing after surgery at which the original cohort of patients who improved was reduced by half. Median times for all categorical independent variables were also estimated using this analysis. The prognostic factors were determined using Cox Proportional Hazard regression. The variables were first analyzed using simple Cox regression. Subsequently, variables with a significant p-value and those which were considered clinically and biologically important were analyzed in multiple Cox regression (variables selection). In multivariable testing, variables with a significant p-value and an alpha error of up to 5% were accepted. Statistical analyses and data entry were performed using IBM SPSS Statistics version 22.0 (IBM Corp, Armonk, NY, USA) \[[@B15-ijerph-17-00310]\] and Statistical Data Analysis Software (STATA), version 14.0 (StataCorp LP, College Station, TX, USA) \[[@B16-ijerph-17-00310]\].

2.4. Ethical Consideration {#sec2dot4-ijerph-17-00310}
--------------------------

The study was approved by the Human Research Ethics Committee of Universiti Sains Malaysia \[USM/JEPEM/17070326\] and was registered under the National Medical Research Registry, Ministry of Health Malaysia. The conduct of the study followed the tenets of the declaration of Helsinki.

3. Results {#sec3-ijerph-17-00310}
==========

3.1. Overall Characteristics {#sec3dot1-ijerph-17-00310}
----------------------------

[Table 1](#ijerph-17-00310-t001){ref-type="table"} shows the demographic and clinical features of our study subjects. There were 134 patients who met the inclusion and exclusion criteria. In total, 67 (50%) vision losses were reported, while the remaining 67 (50%) were censored observations. Among the censored group, 18 cases were due to loss to follow up (27%). The gender distribution was approximately equal, with 67 (50%) males and 67 (50%) females. The median age was 56.00 years (IQR ± 10.00) and the median duration of DM was 14.00 years (IQR ± 10.00).

The majority of patients (91.0%) had hypertension, while about a third (32.8%) had chronic kidney disease and almost a quarter (26.1%) had IHD. Pre-operatively, 77 patients (57.5%) had TRD with macula involvement. Post-vitrectomy, half of this cohort experienced VH, while another one-third had TRD. Based on Kaplan--Meier analysis, the overall median time to vision loss was 14.63 months (95% CI: 9.95, 19.32) ([Figure 1](#ijerph-17-00310-f001){ref-type="fig"}). [Figure 1](#ijerph-17-00310-f001){ref-type="fig"} shows the median probability time of 14.63 months, i.e., the estimated median time at which 50% of the patients had vision loss. [Figure 1](#ijerph-17-00310-f001){ref-type="fig"} provides a visual illustration of the probability of vision loss at a given time interval (i.e., month).

The Kaplan--Meier curve shows the time to vision loss for individual study subjects throughout the duration of the study. The horizontal lines along the X-axis represent the survival duration in months, i.e., the duration until vision loss occurs. All subjects begin the analysis at the same point and are considered 'survivors' until an event of interest (vision loss) occurs. Each event is marked by a sharp downward deflection of the graph (vertical line). Censored patients (i.e., subject maintaining vision or lost to follow up) are also marked on the graph.

3.2. Unadjusted Factors of Vision Loss {#sec3dot2-ijerph-17-00310}
--------------------------------------

Using univariable analysis of simple Cox regression, only one variable, IHD, was statistically significant (*p*-value = 0.009). Five other factors with a *p*-value less than 0.25 were duration of DM (*p*-value = 0.230), TRD with macula involvement (*p*-value = 0.134), post-operative VH (*p*-value = 0.102), post-operative TRD (*p*-value = 0.095) and post-operative ERM (*p*-value = 0.171) ([Table 2](#ijerph-17-00310-t002){ref-type="table"}).

3.3. Prognostic Factors of Vision Loss {#sec3dot3-ijerph-17-00310}
--------------------------------------

After multivariable analysis evaluating for age, duration of DM, gender, pre-operative VH, pre-operative TRD with macula off, pre-operative combined TRD/RRD, CKD, pre-operative NVI, IHD, post-operative TRD, post-operative VH and post-operative ERM, we found that only the variable IHD (*p*-value = 0.010) was significantly associated with vision loss. The preliminary main effect model was achieved.

4. Discussion {#sec4-ijerph-17-00310}
=============

Vitrectomy surgery has been observed to improve the vision-related quality of life in patients with PDR, likely due to its association with visual gains \[[@B17-ijerph-17-00310]\]. However, most studies assessing the functional effect of vitrectomy in DR fail to discuss the time-limited nature of these gains \[[@B17-ijerph-17-00310],[@B18-ijerph-17-00310]\]. To the best of our knowledge, this study is the first to identify the survival time of visual gains among patients with visual improvement post vitrectomy for complications PDR. We also evaluate the factors associated with vision loss in this cohort.

We found that 50% of our cohort experienced visual loss during the study period. This may seem to compare unfavorably with other published results of vitrectomy \[[@B11-ijerph-17-00310],[@B19-ijerph-17-00310]\], but differences in study objective may serve to explain the discrepancy. Most studies evaluating the outcome of vitrectomy measure success based on visual acuity at a single point in time, and compare their results of patients with improved vision to those who experienced no improvement with surgery. In contrast, the focus of our study was only on those who improved with surgery; we were interested in the duration of time that these patients could hope to enjoy their newly regained vision. Our 14.63 months survival time of visual gains post vitrectomy reflects the median time from surgery until 50% of our cohort sustained visual loss. These results may be useful to temper patient expectations during counseling for surgery. However, considering the life expectancy of diabetic patients requiring vitrectomy and their 5-year survival rates, which may be as low as 68%, the decision for vitrectomy may still be seen as a worthwhile investment to optimize the quality of their remaining years of life \[[@B20-ijerph-17-00310],[@B21-ijerph-17-00310],[@B22-ijerph-17-00310],[@B23-ijerph-17-00310],[@B24-ijerph-17-00310]\]`.`

We observed that the variable IHD was significantly associated with vision loss among patients who underwent vitrectomy for complications of PDR. To the best of our knowledge, our study is the first to identify IHD as a prognostic factor for vision loss among PDR patients. IHD has previously been identified as a poor prognostic factor for survival after diabetic vitrectomy, with 50% of these patients dying within 3.5 years of surgery \[[@B25-ijerph-17-00310]\]. Cardiovascular disease is in fact the most common cause of death in patients undergoing vitrectomy for diabetic retinopathy \[[@B24-ijerph-17-00310]\]. We believe that these results reflect the underlying insufficiency of the vasculature in diabetic patients. Diabetic retinopathy is associated with micro- and macrovascular complications of diabetes, and its progression increases the risk of stroke and cardiovascular disease \[[@B26-ijerph-17-00310]\]. T2DM patients with PDR have been observed to have a higher risk of cardiovascular disease \[[@B27-ijerph-17-00310],[@B28-ijerph-17-00310]\] than those without PDR. This association is supported by studies demonstrating that retinopathy is associated with a higher risk of abnormal perfusion \[[@B29-ijerph-17-00310]\], possibly related to impaired arteriolar dilation in response to hypoxia \[[@B30-ijerph-17-00310]\]. As no overt associations such as VH, TRD and ERM were found in our patients who experienced vision loss, we hypothesize that the cause for their visual deterioration is related to retinal ischemia. Although differences in the pathophysiology of macro and microvascular disease are beyond the scope of this discussion, both retinopathy and coronary artery disease share a common end pathway of endothelial dysfunction. This may explain the observed benefit of statins in these conditions, which have been shown to have immune-modulatory effects on inflammation \[[@B31-ijerph-17-00310],[@B32-ijerph-17-00310]\] and endothelial dysfunction \[[@B33-ijerph-17-00310],[@B34-ijerph-17-00310],[@B35-ijerph-17-00310],[@B36-ijerph-17-00310]\].

Post-operative VH and TRD were not uncommon in our cohort, and reflect the published rates of these complications \[[@B10-ijerph-17-00310],[@B37-ijerph-17-00310]\]. However, they did not have a statistically significant effect on maintenance of visual gains post vitrectomy. Our study also found that other factors traditionally associated with a poor visual outcome post diabetic vitrectomy (such as pre-operative NVI \[[@B38-ijerph-17-00310],[@B39-ijerph-17-00310]\], and TRD \[[@B11-ijerph-17-00310]\]) were not significantly associated with vision loss. This is due to difference in study design, as discussed above; most studies of diabetic vitrectomy evaluated overall visual outcome in all vitrectomy cases, while we more concerned with maintenance of visual gains within the group of patients who experienced visual improvement post vitrectomy. In the former, pre-operative conditions like long-standing macular detachment may have limited visual gains. In the latter, as discussed above, systemic risk factors may play a greater role than previously acknowledged, because although post-operative ocular complications like recurrent VH may be managed with a repeat vitrectomy, the underlying vascular dysfunction in these patients remain to be addressed.

Our study is not without its limitations, such as selection bias, which may have resulted in sampling a greater number of subjects with visual loss post-vitrectomy as those with good vision may have been tempted to default follow-up. Secondly, although patients were assumed to have macular ischemia in the absence of any overt causes of poor final visual acuity, objective documentation such as via fundus fluorescein angiography was generally not available. Finally, due to the retrospective nature of this study, the diagnosis of IHD was loosely defined, and further relevant information such as medication and smoking history could not be ascertained. Thus, the possibility remains that these and other unmeasured confounders may explain the observed association. Prospective designs with special attention to evaluation of cardiovascular risk factors, lifestyle and medication history may address these issues, although loss to follow-up remains a valid concern, especially over long periods of time.

The perceived value of sight can perhaps best be illustrated by the results of online surveys conducted among the general public, in which loss of sight is rated as the worst possible health outcome \[[@B40-ijerph-17-00310],[@B41-ijerph-17-00310]\]. On average, respondents chose 4.6 years of perfect health over 10 years of life with complete sight loss \[[@B41-ijerph-17-00310]\]. The unique strength of our study is thus its identification of the survival time of vitrectomy-related visual gains, which will not only assist clinicians in providing patients with realistic expectations of their post-surgical outcome, but also guide the development of timely post-operative review schedules. Knowledge of the risk factors for vision loss also allows identification of high-risk patients. Future research involving risk factor modification in this group may shed further information on the significance of these findings.

5. Conclusions {#sec5-ijerph-17-00310}
==============

Approximately 50% of patients with initial post vitrectomy visual improvement will maintain their vision for at least 14 months after surgery. The hazards of visual loss are higher in those with pre-existing IHD.
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###### 

Characteristics of subjects with visual improvement post vitrectomy for complications of PDR (n = 134).

  Characteristics                             Vision Loss   Censored    Total
  ------------------------------------------- ------------- ----------- ------------
  Gender                                                                
  Male \*                                     37 (55.2)     30 (44.8)   67 (50.0)
  Female                                      30 (44.8)     37 (55.2)   67 (50.0)
  Ethnicity                                                             
  Non-Malay \*                                5 (7.5)       8 (11.9)    13 (9.7)
  Malay                                       62 (92.5)     59 (88.1)   121 (90.3)
  Family history of DM                                                  
  Yes                                         67 (100)      67 (100)    134 (100)
  Type of DM                                                            
  Type II                                     67 (100)      67 (100)    134 (100)
  Anti-diabetic medication                                              
  Oral medication \*                          12 (17.9)     13 (19.4)   25 (18.7)
  Insulin                                     55 (82.1)     54 (80.6)   109 (81.3)
  Laterality                                                            
  Right eye \*                                28 (41.8)     31 (46.3)   59 (44.0)
  Left eye                                    39 (58.2)     36 (53.7)   75 (56.0)
  Pre-operative VH                                                      
  Yes                                         55 (82.1)     55 (82.1)   110 (82.1)
  No \*                                       12 (17.9)     12 (17.9)   24 (17.9)
  Pre-operative TRD with macula involvement                             
  Yes                                         37 (55.2)     40 (59.7)   77 (57.5)
  No \*                                       30 (44.8)     27 (40.3)   57 (42.5)
  Pre-operative combined TRD/RRD                                        
  Yes                                         9 (13.4)      5 (7.5)     14 (10.5)
  No \*                                       58 (86.6)     62 (92.5)   120 (89.5)
  Pre-operative NVI                                                     
  Yes                                         3 (4.5)       2 (3.0)     5 (3.7)
  No \*                                       64 (95.5)     65 (97.0)   129 (96.3)
  Hypertension                                                          
  Yes                                         63 (94.0)     59 (88.1)   122 (91.0)
  No \*                                       4 (6.0)       8 (11.9)    12 (9.0)
  IHD                                                                   
  Yes                                         22 (32.8)     13 (19.4)   35 (26.1)
  No \*                                       45 (67.2)     54 (80.6)   99 (73.9)
  CKD                                                                   
  Yes                                         26 (38.8)     18 (26.8)   44 (32.8)
  No \*                                       41 (61.2)     49 (73.1)   90 (67.2)
  CVA                                                                   
  Yes                                         1 (1.5)       0 (0)       1 (0.8)
  No \*                                       66 (985)      67(100)     133 (99.2)
  Post-Op VH                                                            
  Yes                                         40 (59.7)     27 (40.3)   67 (50.0)
  No \*                                       27 (40.3)     40 (59.7)   67 (50.0)
  Post-Op TRD                                                           
  Yes                                         24 (35.8)     19 (28.4)   43 (32.1)
  No \*                                       43 (64.2)     48 (71.6)   91 (67.9)
  Post-Op RRD                                                           
  Yes                                         5 (7.5)       2 (3.0)     7 (5.2)
  No \*                                       62 (92.5)     65 (97.0)   127 (94.8)
  Post-op NVI                                                           
  Yes                                         8 (11.9)      3 (4.5)     11 (8.2)
  No \*                                       59 (88.1)     64 (95.5)   123 (91.8)
  Post-op ERM                                                           
  Yes                                         13 (19.4)     11 (16.4)   24 (17.9)
  No \*                                       54 (80.6)     56 (83.6)   110 (82.1)

Note. DM: Diabetes mellitus, VH: Vitreous hemorrhage, TRD: Tractional retinal detachment, RRD: Rhegmatogeneous retinal detachment, NVI: Neovascularization of iris, IHD: Ischemic heart disease, CKD: Chronic kidney disease, CVA: Cerebrovascular accident, ERM: Epiretinal membrane; \* Reference group.
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###### 

Prognostic factors associated with vision loss among subjects with visual improvement post vitrectomy for complications of proliferative diabetic retinopathy (Simple Cox regression) (n = 134).

  Variables                                   Regression Coefficient (b)   Crude Hazard Ratio (95% CI) ^1^   Wald Statistic   *p*-Value
  ------------------------------------------- ---------------------------- --------------------------------- ---------------- -----------
  Age                                         0.02                         1.02 (0.98, 1.06)                 0.28             0.279
  Gender                                                                                                                      
  Male \*                                     0                            1.00                              \-               \-
  Female                                      0.01                         1.10 (0.63, 1.64)                 0.95             0.954
  Ethnicity                                                                                                                   
  Non-Malay \*                                0                            1.00                              \-               \-
  Malay                                       0.33                         1.39 (0.56, 3.47)                 0.46             0.477
  Duration of DM                              0.02                         1.02 (0.99, 1.06)                 0.24             0.230
  Anti-diabetic medication                                                                                                    
  Oral medication \*                          0                            1.00                              \-               \-
  Insulin                                     0.27                         1.31 (0.70, 2.46)                 0.39             0.398
  Laterality                                                                                                                  
  Right eye \*                                0                            1.00                              \-               \-
  Left eye                                    −0.01                        1.00 (0.61, 1.63)                 1.00             0.998
  Pre-operative VH                                                                                                            
  Yes                                         −0.35                        0.70 (0.37, 1.31)                 1.29             0.269
  No \*                                       0                            1.00                              \-               \-
  Pre-operative TRD with macula involvement                                                                                   
  Yes                                         0.38                         1.47 (0.89, 2.43)                 0.13             0.134
  No \*                                       0                            1.00                              \-               \-
  Pre-operative combined TRD/RRD                                                                                              
  Yes                                         0.10                         1.11 (0.54, 2.24)                 0.78             0.782
  No \*                                       0                            1.00                              \-               \-
  Pre-operative NVI                                                                                                           
  Yes                                         0.56                         1.75 (.55, 5.g)                   0.38             0.344
  No \*                                       0                            1.00                              \-               \-
  IHD                                                                                                                         
  Yes                                         0.69                         1.99 (1.18, 3.35)                 0.01             0.009
  No \*                                       0                            1.00                              \-               \-
  CKD                                                                                                                         
  Yes                                         0.11                         1.11 (0.68, 1.82)                 0.67             0.668
  No \*                                       0                            1.00                              \-               \-
  Post-Op VH                                                                                                                  
  Yes                                         0.41                         1.50 (0.92, 2.45)                 0.10             0.102
  No \*                                       0                            1.00                              \-               \-
  Post-Op TRD                                                                                                                 
  Yes                                         0.43                         1.54 (0.93, 2.56)                 0.10             0.095
  No \*                                       0                            1.00                              \-               \-
  Post-op ERM                                                                                                                 
  Yes                                         −0.43                        0.65 (0.35, 1.20)                 0.15             0.171
  No \*                                       0                            1.00                              \-               \-

Note. 95% CI = confidence interval; ^1^ Simple Cox proportional hazard regression; DM: Diabetes mellitus, VH: Vitreous hemorrhage, TRD: Tractional retinal detachment, RRD: Rhegmatogeneous retinal detachment, NVI: Neovascularization of iris, IHD: Ischemic heart disease, CKD: Chronic kidney disease, ERM: Epiretinal membrane; \* Reference group.
